MicroRNAs in patients on chronic hemodialysis (MINOS Study)

Cristina Emilian, Emeline Goretti, Fernand Prospert, Dominique Pouthier, Pierre Duhoux, Georges Gilson, Yvan Devaux*, Daniel R. Wagner

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

27 Citations (Scopus)


Background and objectives Diagnosis of acute myocardial injury with biomarkers is difficult in patients with advanced renal failure. Circulating microRNAs are promising new biomarkers of myocardial injury. It is unknown whether levels of microRNAs are affected in patients undergoing hemodialysis. Design, setting, participants, & measurements High-sensitivity cardiac troponin T (hsTnT) and cardiac-enriched miR-499 were measured in 41 patients with ESRD undergoing hemodialysis and 41 controls. Results Levels of hsTnT and miR-499 were highly elevated in patients with ESRD compared with controls (>80-fold increase; P<0.001). Among patients with ESRD, 98% had positive hsTnT levels and 46% had positive miR-499 levels. Levels of troponins were not affected by hemodialysis. However, miR-499 levels were decreased after hemodialysis (6.5-fold decrease; P=0.002). Conclusions Both miR-499 and troponins are elevated in patients with advanced renal failure. However, whereas levels of troponins are unaffected by hemodialysis, this is not the case for miR-499. Therefore, these observations mitigate the potential of miR-499 as a marker of myocardial injury in patients with ESRD.

Original languageEnglish
Pages (from-to)619-623
Number of pages5
JournalClinical journal of the American Society of Nephrology : CJASN
Issue number4
Publication statusPublished - 1 Apr 2012


Dive into the research topics of 'MicroRNAs in patients on chronic hemodialysis (MINOS Study)'. Together they form a unique fingerprint.

Cite this